Posard Matthew L. 4
4 · HALOZYME THERAPEUTICS, INC. · Filed Jun 13, 2024
Insider Transaction Report
Form 4
Posard Matthew L.
Director
Transactions
- Sale
Common Stock
2024-06-11$50.01/sh−10,000$500,110→ 109,755 total - Sale
Common Stock
2024-06-12$50.62/sh−10,000$506,190→ 99,755 total
Footnotes (3)
- [F1]Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.00 to $50.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F2]Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.
- [F3]Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.50 to $50.935. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.